___

• 1.Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Gui-delines for the management of transfusion dependent thalas-saemia (TDT). 3rd ed. Thalassaemia International Federati-on TIF Publication, 2014; 17-65
• 2.Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cap-pellini MD,Del Vecchio GC, et al. Survival and complicati-ons in patients with thalassemia major treated with transfu-sion and deferoxamine. Haematologica 2004; 89:1187-93.
• 3.Vogiatzi MG, Macklin EA, Trachtenberg FL, Fung EB, Che-ung AM, Vichinsky E, et al. Differences in the prevalence ofgrowth, endocrine and vitamin D abnormalities among the va-rious thalassaemia syndromes in North America. Br J Hae-matol 2009; 46:546-56.
• 4.Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, MittelmanS. Predicting pituitary iron and endocrine dysfunction. AnnN Y Acad Sci 2010; 1202:123-8.
• 5.De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia In-ternational Federation Study Group on Growth and Endocri-ne Complications in Thalassaemia. Prevalence of endocrine com-plications and short tature in patients with thalassaemia ma-jor: a multicenter study by the Thalassaemia International Fe-deration (TIF).Pediatr Endocrinol Rev 2004; 2: 249-55.
• 6.Karakaş Z, Karadağ Kİ, Gül N, Demir AA, Darendeliler FF,Dursun M. Evaluation Of Pituitary Iron Overload in Patientswith Transfusion Dependent Thalassemia. Meeting Abstract,Thalassemia International Federation Congress, Athen,Greece, Kasım 2017.
• 7.Kattamis C, Liakopoulou T, Kattamis A. Growth and develop-ment in children with thalassaemia major. Acta Paediatr ScandSuppl 1990; 366:111-7.
• 8.Aydınok Y, Darcan S, Polat A, Kavakli K, Nigli G, Coker M,et al. Endocrine complications in patients with beta-thalas-semia major. J Trop Pediatr 2002; 48: 50-4.
• 9.Noetzli LJ, Panigrahy A, Mittelman SD, Hyderi A, Dongelyan A,Wood JC. Piuitary iron and volume predict hypogonadism in trans-fusional iron overload. Am J Hematol 2012; 87:167-171.
• 10.Güler E, Patıroğlu T, Çaksen H, Özdemir MA, Kurtoğlu S, Ken-dirci M. Talasemi majörlü vakalarda endokrin komplikasyon-ların değerlendirilmesi. Türk Pediatri Arşivi 1999; 34: 174-181.
• 11.Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanc-tis V, Melevendi C, et al. Growth and sexual maturation in tha-lassemia major. J Pediatr 1985; 106:150-5.
• 12.Landau H, Gross V, Dagan I, Palti Z, Rachmilewitz EA, SpitzIM. Growth and sexual development before and after sex ste-roid therapy in patients with thalassemia major. Arch InternMed 1984; 144: 2341-6.
• 13.Arrigo T, Crisafulli G, Meo A, Sturiale M, Lombardo F, Mi-celi M, et al. Glucose tolerance, insulin secretion and perip-heral sensitivity in thalassaemia major. J Pediatr EndocrinolMetab 1998; 3: 863-6.
• 14.De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gre-gorio F. Insulin dependent diabetes in thalassaemia. Arch DisChild 1988; 63:58-62.
• 15.Zuppinger K, Molinari B, Hirt A, Imbach P, Gugler E, TonzO, et al. Increased risk of diabetes mellitus in beta- thalasse-mia major due to iron overload. Helv Paediatr Acta 1979; 34:197-207.
• 16.Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C,Sacchetti L et al. Insulin resistance and hyperinsulinemia inhomozygous beta- thalassemia. Metabolism 1995; 44:281-6.
• 17.Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS,Pearson HA, et al. Insulin resistance and hyperinsulinemia inpatients with thalassemia major treated by hypertransfusion.N Engl J Med 1988; 318: 809- 14.
• 18.Bradley B, Prowse SJ, Bauling P, Lafferty KJ. Desferrioxa-mine treatment prevents chronic islet allograft damage. Dia-betes 1986; 35: 550-5.
• 19.Kattamis C. Present and Future of Thalasemia the expert po-ints of view. Uluslararası Talasemi Kongresi ve Yaz Okulu Kon-gre Kitabı. Antalya, Talasemi Federasyonu Yayınları,2013;133-141
• 20.Bradley B, Prowse SJ, Bauling P, Lafferty KJ. Desferrioxa-mine treatment prevents chronic islet allograft damage. Dia-betes 1986; 35: 550-5.
• 21.Masala A, Meloni T, Gallisai D, Alagna S, Rovasio PP, Ras-su S, et al. Endocrine functioning in multitransfused prepu-bertal patients with homozygous beta-thalassemia. J Clin En-docrinol Metab 1984; 58: 667-70.
• 22.Magro S, Puzzonia P, Consarino C, Galati MC, Morgione S,Porcelli D, et al. Hypothyroidısm in patients with thalasse-mia syndromes. Acta Haematol 1990; 84:72-6.
• 23.Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yar-dumian A, et al. High incidence of osteoporosis in thalassae-mia major. J Pediatr Endocrinol Metab 1998; 11: 975-7.
• 24.De Vernejoul MC, Girot R, Gueris J, Cancela L, Bang S, Bie-lakoff J, et al. Calcium phosphate metabolism and bone disea-se in patients with homozygous thalassemia. J Clin Endocri-nol Metab. 1982; 54: 276-81.
• 25.Mautalen CA, Kvicala R, Perriard D, Bugnard E, Rossi E, Du-hart J. Case report: hypoparathyroidısm and iron storage di-sease. Treatment with 25-hydroxy- vitamin D3. Am J Med Sci1978; 276: 363-8.
• 26.Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanc-tis V, Melevendi C, et al. Growth and sexual maturation in tha-lassemia major. J Pediatr 1985; 106:150-5.
• 27.Pratico G, Di Gregorio F, Caltabiano L, Palano GM, Caru-so-Nicoletti M. Calcium phosphate metabolism in thalassemia.Pediatr Med Chir 1998; 20:265-8.
• 28.Voskaridou E, Terpos E. New insights into the pathophysio-logy and management of osteoporosis in patients with beta tha-lassaemia. Br J Haematol 2004; 127: 127-139.
• 29.Lassman MN, O' Brien RT, Pearson HA, Wise JK, Donabe-dian RK, Felig P, et al. Endocrine evaluation in thalassemiamajor. Ann N Y Acad Sci 1974; 232: 226-37.